ALDH7A1 and idiopathic pulmonary fibrosis: Intracellular potentiation of cAMP has recently garnered renewed interest as an antifibrotic therapy in IPF and non‐IPF pulmonary fibrosis following the promising phase 3 results of the PDE inhibitor nerandomilast [54, 55].